Antimicrobial Peptide LL-37 Reduces Gum Disease Inflammation by 40-75% by Neutralizing Bacterial Toxins | Research

The takeaway

The antimicrobial peptide LL-37 and polymyxin B each reduced endotoxin activity in oral biofilms by over 90% and decreased pro-inflammatory cytokines by 40-75%, offering novel approaches to periodontal disease.

>90% toxin neutralization
LL-37 reduced endotoxin activity in oral biofilms by over 90%, leading to 40-75% reduction in inflammatory markers

What the researchers found

LL-37 and polymyxin B reduced endotoxin activity in oral biofilms by >90% and decreased pro-inflammatory cytokine secretion by 40-75% while preserving anti-inflammatory cytokines, with LL-37 showing stronger IRF pathway inhibition.

Why it matters

Periodontal disease affects nearly half of adults. An approach that neutralizes bacterial toxins rather than killing all bacteria could provide targeted treatment that preserves the beneficial oral microbiome.

How the study worked

Endotoxin measurement (rFC assay) and immune stimulation assays (THP-1 and THP-1 Dual cells, NF-κB/IRF pathway assessment, cytokine profiling) using saliva and subgingival biofilm from 324 participants (healthy, gingivitis, periodontitis).

What this study cannot tell us

In vitro study only. Clinical feasibility of delivering LL-37 to periodontal pockets not addressed. Cost and stability of peptide-based treatments may be challenges.

How to read the evidence

Well-designed in vitro study with large sample pool (324 participants) and comprehensive immune pathway analysis. Clinical application needs validation.

When this study was published

Published in 2025.

The bigger picture

This anti-virulence approach using antimicrobial peptides represents a paradigm shift in periodontal treatment—targeting the damage caused by bacteria rather than the bacteria themselves.

Questions still open

Could LL-37-based mouth rinses or gels effectively treat periodontitis in clinical trials?
Would combining LL-37 with polymyxin B provide synergistic anti-inflammatory benefits?
How long does the endotoxin-neutralizing effect last in the oral environment?

Common questions

How does LL-37 help with gum disease?

Instead of killing bacteria, LL-37 neutralizes their toxins (endotoxins). This reduces the inflammation that causes gum disease damage by 40-75% while leaving beneficial bacteria unharmed.

Is this treatment available?

Not yet. This is laboratory research showing the concept works. LL-37-based treatments for gum disease would need to be developed into products like gels or rinses and tested in clinical trials.

Read the original research

Modulation of LPS-associated virulence activity for reduction of periodontal inflammatory burden.

Frontiers in microbiology, 17, 1728315

View on PubMed ↗Publisher’s paper ↗

Citation

Dong, Anbo; Lehto, Markku; Putaala, Jukka; Paju, Susanna; Pussinen, Pirkko; Zaric, Svetislav. (2026). Modulation of LPS-associated virulence activity for reduction of periodontal inflammatory burden.. Frontiers in microbiology, 17, 1728315. https://doi.org/10.3389/fmicb.2026.1728315